Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-22T16:43:17.347Z Has data issue: false hasContentIssue false

The effects of prolonged exposure to high glucose on glucose metabolism and metabolomic profiles in pancreatic β-cells

Published online by Cambridge University Press:  13 January 2009

Rights & Permissions [Opens in a new window]

Abstract

Type
Abstract
Copyright
Copyright © The Authors 2009

Diabetes mellitus affects >180 million individuals worldwide(1). Type 2 diabetes is characterised by impaired insulin secretion from pancreatic β-cells and increased insulin resistance in peripheral tissues resulting in hyperglycaemia. Long-term exposure to high glucose concentrations has been shown to cause pancreatic β-cell apoptosis(Reference Kim, Lee, Suh, Hong, Choi, Lim, Song, Gao and Jung2), impaired insulin secretion(Reference Eizirik, Korbutt and Hellerstrom3) and impaired mitochondrial function(Reference Krauss, Zhang, Scorrano, Dalgaard, St-Pierre, Grey and Lowell4, Reference Patane, Anello, Piro, Vigneri, Purrello and Rabuazzo5). The resulting glucotoxicity is thought to be a contributing factor to the deterioration of pancreatic β-cell function and mass, which leads to progression of the disease. The current study used the novel approach of combining flux analysis and metabolomic profiling to investigate the effects of high glucose levels on metabolic pathways and thus enhance the understanding of the mechanisms of glucotoxicity.

BRIN-BD11 cells were cultured for 20 h with 11.1 or 25 mm-glucose. Following treatment cells were incubated in 1.1 mm-glucose for 20 min and then stimulated with 14 mm-glucose for 1 h. Metabolic extracts of the cells were then prepared and 1H NMR spectra were obtained. Glucose uptake and insulin secretion were determined from the media. Flux studies were performed under similar conditions using [U-13C]glucose and 13C NMR spectra were obtained.

Following prolonged exposure to 25 mm-glucose there was a significant decrease in glucose-stimulated insulin secretion (ng/mg protein) from 35.1 (sd 1.2) to 29.5 (sd 2.5; P<0.03) and a significant decrease in glucose uptake (μmol/mg protein) from 37.7 (sd 4.9) to 32.6 (sd 4.8; P<0.05), indicating mild glucotoxicity. Principle component analysis of the 1H NMR spectra showed a distinct separation between the high-glucose-treated group and the control group (11.1 mm-glucose). Preliminary interrogation of the corresponding loadings plot identified alanine and aspartate as being decreased and γ-aminobutyric acid and glycine as being increased in the high-glucose-treated group. Previous studies have shown that alanine has a potentiating effect on glucose-stimulated insulin secretion and undergoes substantial metabolism in BRIN-BD11 β-cells(Reference Brennan, Shine, Hewage, Malthouse, Brindle, McClenaghan, Flatt and Newsholme6), whereas γ-aminobutyric acid production has been associated with a negative effect on insulin secretion(Reference Dong, Kumar and Zhang7). Flux analysis of the 13C NMR spectra showed that following prolonged exposure to high glucose levels the amount of 13C label at glutamate C4 decreased significantly from 33.8 nmol/mg protein to 27.7 nmol/mg protein (P<0.05) and the percentage acetyl-CoA that was labelled also decreased. These changes are indicative of a reduction in flux through pyruvate dehydrogenase into the TCA cycle.

Overall, these results show that exposure to high glucose levels cause changes in metabolic flux into the TCA cycle and production of certain key amino acids. The novel combination of metabolic flux and metabolomic analyses gives an enhanced understanding of the underlying mechanisms of glucotoxicity. Future experiments will be directed at expanding this knowledge further and investigating the effects of a combination of high glucose and high lipid exposure.

References

2.Kim, WH, Lee, JW, Suh, YH, Hong, SH, Choi, JS, Lim, JH, Song, JH, Gao, B & Jung, MH (2005) Diabetes 54, 26022611.10.2337/diabetes.54.9.2602CrossRefGoogle Scholar
3.Eizirik, DL, Korbutt, GS & Hellerstrom, C (1992) J Clin Invest 90, 12631268.10.1172/JCI115989CrossRefGoogle Scholar
4.Krauss, S, Zhang, CY, Scorrano, L, Dalgaard, LT, St-Pierre, J, Grey, ST & Lowell, BB (2003) J Clin Invest 112, 18311842.10.1172/JCI200319774CrossRefGoogle Scholar
5.Patane, G, Anello, M, Piro, S, Vigneri, R, Purrello, F & Rabuazzo, AM (2002) Diabetes 51, 27492756.10.2337/diabetes.51.9.2749CrossRefGoogle Scholar
6.Brennan, L, Shine, A, Hewage, C, Malthouse, JP, Brindle, KM, McClenaghan, N, Flatt, PR & Newsholme, P (2002) Diabetes 51, 17141721.10.2337/diabetes.51.6.1714CrossRefGoogle Scholar
7.Dong, H. Kumar, M, Zhang, Y et al. (2006) Diabetologia 49, 697705.10.1007/s00125-005-0123-1CrossRefGoogle Scholar